Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3408 - Interim Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Supportive Care and Symptom Management

Tumour Site

Colon and Rectal Cancer

Presenters

Zorana Maravic

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Z. Maravic1, J.M. Borras2, E. Espin Basany3, Á. Petrányi4, Z. Kapitany5, P. Rakonczai6, A. Benedict7, N. Muszbek8

Author affiliations

  • 1 Group And Project Development, EuropaColon, SP1 3TR - Salisbury/GB
  • 2 Hospitalet De Llobregat, Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 3 Unidad De Cirugía De Colon Y Recto, Hospital Valle de Hebron, Universitat Autonoma de Barcelona, 08035 - Barcelona/ES
  • 4 Onkoradiológia, Egyesített Szent István és Szent László Kórház, Budapest/HU
  • 5 Dept. Of Physiotherapy, Semmelweis University Faculty of Health Sciences, 1088 - Budapest/HU
  • 6 Modeling And Simulation, Evidera, 1022 - Budapest/HU
  • 7 Modelling And Simulation, Evidera Inc., 1022 - Budapest/HU
  • 8 Modelling And Simulations, Evidera (European Headquarter), W6 8DL - London/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3408

Background

With increasing emphasis on patients’ voices, EuropaColon, a European CRC patient organization, conducted a cross-sectional European survey on unmet needs in mCRC, in 12 countries. The aim was to better understand the challenges, needs and the health-related quality of life (HRQoL). The objective of this work is to report the preliminary results for Hungary (HU), Poland (PL), Serbia (RS) and Spain (ES).

Methods

IRB approval was obtained. Clinicians, and nurses with partner organizations of EuropaColon recruited patients. The survey had two sections: treatment-related information and HRQoL. The former comprised questions on timing of diagnosis/treatment, multidisciplinary team discussion (MDT), type of treatments received, and information on treatments and side-effects. Both paper-based and on-line completion were available. Single data entry was done by EuropaColon. Descriptive analyses were carried out in Excel. No imputation of missing data was done.

Results

548 surveys were analyzed. Completion rates were high. Most responders were treated in public hospitals and 85-92% in HU, ES and PL and 57% in RS were undergoing treatment at the time. Most patients (82%) received treatments within 3 months after diagnosis with CRC, 16% within first 2 weeks. 60% underwent MDT discussion and were informed about the outcome. Proportions however varied between countries, with lowest for PL (46%) and highest for RS (74%). Proportion of patients feeling their views were considered prior starting treatment varied (from 30% in RS to 83% in HU). Most patients had surgery and chemotherapy (83% and 91%), 21% radio- and 9% targeted therapy. Specific therapies however were not given in 13-23% of cases. Patients were relatively informed about side effects (73%). A fifth of patients received molecular test, from a low 6% in RS up to 34% in PL.

Conclusions

Among mCRC patients in HU, ES, RS and PL the degree of information varies. Patients know about MDT and are informed about potential side effects. However, the specific treatment is not well known, and molecular testing is rare. Variations across countries need to be investigated further. Study limitations include cross-sectional design and single data entry.

Clinical trial identification

Legal entity responsible for the study

EuropaColon.

Funding

Merck, BMS, Sandoz, Sirtex.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.